GPR40 is known as free fatty acid receptor 1. Currently, HD-6277, a novel GPR40 agonist, is being developed by Hyundai Pharm in first in human study. The aim of this study was to determine the effects of the novel GPR40 agonist. HD-6277 is a highly potent, selective and orally available small molecule agonist. The potency was measured in vitro and in vivo studies. In vitro potency was determined by HD-6277, TAK-875 and GW95(EC50, <10 nM, 27 nM and 14 nM) in stably hGPR40 expressed CHO cells. Selective GPR40 activity of HD-6277 was evaluated by GPCR panel assay.In vivo glucose lowering effect was determined by oral glucose tolerance test (OGTT) and HbA1c in Sprague-Dawley (SD) rats and various type 2 diabetes rats, respectively. Oral administration of HD-6277 (0.1∼10 mg/kg) once daily reduced plasma glucose excursion and enhanced insulin secretion in GK, DIO, OLETF and ZDF rats. Antidiabetic efficacy compared with Metformin, Glimepiride, Linagliptin, Empagliflozin, Rosiglitazone and Fasiglifam respectively. HD-6277 treatment showed potent anti-hyperglycemic effects than commercially available antidiabetic drugs. GSIS was assessed in INS-1 cells and rats with sulfonylurea and glinides. HD-6277 enhanced insulin excursion in high glucose condition, whereas in low glucose circumstance was not, thus hypoglycemic risk was low. Repeat dosing for 7day in SD rats, glibenclamide (10 mg/kg) and nateglinide (50 mg/kg) caused hypoglycemia but HD-6277 (100 mg/kg) was not.

In conclusion, HD-6277 shows a promising new drug candidates to treat type 2 diabetes mellitus.


D. Kim: Employee; Self; Hyundai Pharm. Corp. C. Kim: Employee; Self; Hyundai Pharm. corp.. H. Choi: None. G. Yang: Employee; Self; Hyundai Pharm. CORP. S. Kang: Employee; Self; Hyundai Pharm. corp. S. Lee: Employee; Self; Hyundai Pharm. CORP. K. Lim: Employee; Self; Hyundai Pharm. corp. M. Park: Employee; Self; Hyundai Pharm.corp. D. Kim: Employee; Self; Hyundai Pharm. CORP. J. Rhee: Employee; Self; Hyundai Pharm. corp..

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at